{"id":"NCT00550459","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients","officialTitle":"A Pilot, Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Effects of Titrated Oral Tolvaptan 15, 30, or 60 mg QD on Cognitive and Neurological Function in Elderly Hyponatremic Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-08","primaryCompletion":"2009-02","completion":"2009-03","firstPosted":"2007-10-29","resultsPosted":"2011-04-28","lastUpdate":"2011-04-28"},"enrollment":57,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hyponatremia"],"interventions":[{"type":"DRUG","name":"Tolvaptan","otherNames":["OPC-41061"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"1","type":"PLACEBO_COMPARATOR"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"Demonstrate an improvement in the composite scores of validated neurocognitive tests in elderly subjects with chronic sub-clinical (i.e., asymptomatic) hyponatremia.","primaryOutcome":{"measure":"Change From Baseline in the Neurocognitive Composite Score of Speed Domains (NCS-SD; Sum of All Correct Speed Domain Z-Scores)","timeFrame":"baseline and Day 22","effectByArm":[{"arm":"Placebo","deltaMin":0.2,"sd":0.61},{"arm":"Tolvaptan (15-60 mg)","deltaMin":0.39,"sd":0.49}],"pValues":[{"comp":"OG000 vs OG001","p":"0.08"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":12,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":28},"commonTop":["Thirst","Pollakiuria","Oedema peripheral","Dizziness","Fatigue"]}}